In this article, Meindert Boysen, deputy chief executive and director of the Centre for Health Technology Evaluation at NICE, explores the proposed changes to NICE’s approach to health technology assessment, what they aim to achieve, and the core benefits for the life sciences sector.
This includes an in-depth look at:
- the key changes that will directly impact the life sciences sector
- how the proposed changes will help to shape the UK environment as the place to make a first product submission
‘With that goal in mind, and as technologies advance, so too must our methods of evaluation. The speed at which the COVID-19 pandemic gripped our health and care systems demanded a new type of response – one that required swiftness, flexibility and adaptation to an ever-changing situation. We rose to meet this demand, and the pandemic provided a catalyst for the type of change we already knew we needed to make.’
